IL1B and cryopyrin-associated periodic syndrome: Remarkably, after 7 days of treatment with IL-1 blockers, in all CAPS patients we observed a marked reduction of both IL-1β (pre-treatment median 83 ng/ml, range 28.5–148; post-treatment median 24.2, range 20–104) and IL-23 (pre-treatment median 1348.6 ng/ml, range 261–2048; post-treatment median 459.4, range 106–1038) secretion by MoDCs (data not shown).